ProQR Therapeutics NV (NASDAQ:PRQR)‘s stock had its “outperform” rating reiterated by investment analysts at Leerink Swann in a research report issued to clients and investors on Friday.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research raised shares of ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a research report on Saturday, September 17th. JMP Securities reissued a “buy” rating on shares of ProQR Therapeutics NV in a research report on Tuesday, September 6th. Janney Montgomery Scott started coverage on shares of ProQR Therapeutics NV in a research report on Wednesday, September 28th. They issued a “neutral” rating and a $7.00 price target for the company. Finally, Chardan Capital initiated coverage on shares of ProQR Therapeutics NV in a research report on Monday, June 20th. They issued a “neutral” rating and a $4.50 price target for the company. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. ProQR Therapeutics NV currently has an average rating of “Buy” and a consensus price target of $14.15.

Analyst Recommendations for ProQR Therapeutics NV (NASDAQ:PRQR)

Shares of ProQR Therapeutics NV (NASDAQ:PRQR) traded up 1.56% during midday trading on Friday, hitting $6.52. 86,631 shares of the stock were exchanged. ProQR Therapeutics NV has a 12 month low of $3.48 and a 12 month high of $16.23. The company’s market cap is $152.22 million. The stock has a 50 day moving average price of $6.40 and a 200-day moving average price of $5.39.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

ProQR Therapeutics NV (NASDAQ:PRQR) last issued its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.00. On average, analysts predict that ProQR Therapeutics NV will post ($2.09) EPS for the current year.

A hedge fund recently raised its stake in ProQR Therapeutics NV stock. Sabby Management LLC boosted its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned about 0.64% of ProQR Therapeutics NV worth $732,000 as of its most recent SEC filing. 39.21% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics NV Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

5 Day Chart for NASDAQ:PRQR

Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with's FREE daily email newsletter.